Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386317731> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4386317731 abstract "Abstract Background An increasing number of clinical studies focus on investigating the use of immunotherapy in the treatment of esophageal cancer. This phase II trial (NEOCRTEC-2001 clinical trial) aimed to assess the safety and efficacy of sintilimab in combination with cisplatin and paclitaxel induction immunochemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC). Methods Patients with primary tumor or bulky lymph nodes that might invade nearby organs were eligible. Treatment started with 2–4 cycles of induction immunochemotherapy, followed by surgery if the tumor was assessed resectable, or by radical concurrent chemoradiotherapy if unresectable. The primary endpoint was pathologically proven complete resection (R0) rate. The secondary end points included pathological complete response (pCR) rate, overall survival (OS), progression-free survival (PFS), adverse events and postoperative complication. Results From September 2020 to now, a total of 34 patients were enrolled. After immunochemotherapy, 21 patients (61.8%) received surgery and 13 (38.2%) did not. All patients underwent McKeown procedure, and median operation time was 295 minutes (range 201–489 minutes). All patients received esophageal reconstruction using gastric tube, and underwent cervical anastomosis. An average of 46.6 lymph nodes were dissected, and positive lymph nodes were observed in 5 of the 21 patients. R0 resection was confirmed in 20 patients (58.8%). One patient underwent R2 resection because of tumor invasion of the aorta. Pathologic complete response was confirmed in 6 patients (6/34, 17.6%), while 5 patients (5/34, 14.7%) had few or no regressive changes (TRG3). Conclusion The treatment strategy of induction immunochemotherapy followed by surgery is promising for patients with locally advanced borderline-resectable esophageal squamous cell carcinoma. The whole results of pathologic response and prognostic value are awaited with interest." @default.
- W4386317731 created "2023-09-01" @default.
- W4386317731 creator A5012541925 @default.
- W4386317731 creator A5015184109 @default.
- W4386317731 creator A5017425083 @default.
- W4386317731 creator A5031597539 @default.
- W4386317731 creator A5045763522 @default.
- W4386317731 creator A5054358636 @default.
- W4386317731 date "2023-08-30" @default.
- W4386317731 modified "2023-09-26" @default.
- W4386317731 title "152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL" @default.
- W4386317731 doi "https://doi.org/10.1093/dote/doad052.032" @default.
- W4386317731 hasPublicationYear "2023" @default.
- W4386317731 type Work @default.
- W4386317731 citedByCount "0" @default.
- W4386317731 crossrefType "journal-article" @default.
- W4386317731 hasAuthorship W4386317731A5012541925 @default.
- W4386317731 hasAuthorship W4386317731A5015184109 @default.
- W4386317731 hasAuthorship W4386317731A5017425083 @default.
- W4386317731 hasAuthorship W4386317731A5031597539 @default.
- W4386317731 hasAuthorship W4386317731A5045763522 @default.
- W4386317731 hasAuthorship W4386317731A5054358636 @default.
- W4386317731 hasBestOaLocation W43863177311 @default.
- W4386317731 hasConcept C121608353 @default.
- W4386317731 hasConcept C126322002 @default.
- W4386317731 hasConcept C141071460 @default.
- W4386317731 hasConcept C143998085 @default.
- W4386317731 hasConcept C168563851 @default.
- W4386317731 hasConcept C203092338 @default.
- W4386317731 hasConcept C2776694085 @default.
- W4386317731 hasConcept C2777546739 @default.
- W4386317731 hasConcept C2778239845 @default.
- W4386317731 hasConcept C2778424827 @default.
- W4386317731 hasConcept C2779742542 @default.
- W4386317731 hasConcept C2780849966 @default.
- W4386317731 hasConcept C31760486 @default.
- W4386317731 hasConcept C71924100 @default.
- W4386317731 hasConceptScore W4386317731C121608353 @default.
- W4386317731 hasConceptScore W4386317731C126322002 @default.
- W4386317731 hasConceptScore W4386317731C141071460 @default.
- W4386317731 hasConceptScore W4386317731C143998085 @default.
- W4386317731 hasConceptScore W4386317731C168563851 @default.
- W4386317731 hasConceptScore W4386317731C203092338 @default.
- W4386317731 hasConceptScore W4386317731C2776694085 @default.
- W4386317731 hasConceptScore W4386317731C2777546739 @default.
- W4386317731 hasConceptScore W4386317731C2778239845 @default.
- W4386317731 hasConceptScore W4386317731C2778424827 @default.
- W4386317731 hasConceptScore W4386317731C2779742542 @default.
- W4386317731 hasConceptScore W4386317731C2780849966 @default.
- W4386317731 hasConceptScore W4386317731C31760486 @default.
- W4386317731 hasConceptScore W4386317731C71924100 @default.
- W4386317731 hasIssue "Supplement_2" @default.
- W4386317731 hasLocation W43863177311 @default.
- W4386317731 hasOpenAccess W4386317731 @default.
- W4386317731 hasPrimaryLocation W43863177311 @default.
- W4386317731 hasRelatedWork W2100029565 @default.
- W4386317731 hasRelatedWork W2145702684 @default.
- W4386317731 hasRelatedWork W2168952713 @default.
- W4386317731 hasRelatedWork W2249625608 @default.
- W4386317731 hasRelatedWork W2394853503 @default.
- W4386317731 hasRelatedWork W2410595505 @default.
- W4386317731 hasRelatedWork W2418663701 @default.
- W4386317731 hasRelatedWork W2591562386 @default.
- W4386317731 hasRelatedWork W363598932 @default.
- W4386317731 hasRelatedWork W4206600817 @default.
- W4386317731 hasVolume "36" @default.
- W4386317731 isParatext "false" @default.
- W4386317731 isRetracted "false" @default.
- W4386317731 workType "article" @default.